scholarly journals Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease–Mineral Bone Disorder

2019 ◽  
Vol 35 (2) ◽  
pp. 333-342
Author(s):  
Colby J Vorland ◽  
Annabel Biruete ◽  
Pamela J Lachcik ◽  
Shruthi Srinivasan ◽  
Neal X Chen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Progression ◽  
Rat Model ◽  
Phosphorus Absorption ◽  
Mineral Bone Disorder ◽  
Bone Disorder ◽  
Kidney Disease Progression

scholarly journals Newly Developed Rat Model of Chronic Kidney Disease–Mineral Bone Disorder

2018 ◽  
Vol 25 (2) ◽  
pp. 170-177 ◽  
Author(s):  
Kentaro Watanabe ◽  
Hideki Fujii ◽  
Shunsuke Goto ◽  
Kentaro Nakai ◽  
Keiji Kono ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Rat Model ◽  
Mineral Bone Disorder ◽  
Bone Disorder

scholarly journals A rat model of chronic kidney disease-mineral bone disorder

2009 ◽  
Vol 75 (2) ◽  
pp. 176-184 ◽  
Author(s):  
Sharon M. Moe ◽  
Neal X. Chen ◽  
Mark F. Seifert ◽  
Rachel M. Sinders ◽  
Dana Duan ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Rat Model ◽  
Mineral Bone Disorder ◽  
Bone Disorder

scholarly journals Intestinal Phosphorus Absorption in Chronic Kidney Disease

Nutrients ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 1364 ◽  
Author(s):  
Elizabeth Stremke ◽  
Kathleen Hill Gallant
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Fibroblast Growth Factor 23 ◽  
Hormonal Changes ◽  
Phosphorus Excretion ◽  
Phosphorus Absorption ◽  
Mineral Bone Disorder ◽  
Bone Disorder ◽  
Intestinal Phosphate Absorption ◽  
Homeostatic Response

Chronic kidney disease (CKD) affects approximately 10% of adults worldwide. Dysregulation of phosphorus homeostasis which occurs in CKD leads to development of CKD-Mineral Bone Disorder (CKD-MBD) and contributes to increased morbidity and mortality in these patients. Phosphorus is regulated by multiple hormones (parathyroid hormone (PTH), 1,25-dihyxdroxyvitamin D (1,25D), and fibroblast growth factor 23 (FGF23)) and tissues (kidney, intestine, parathyroid glands, and bone) to maintain homeostasis. In health, the kidneys are the major site of regulation for phosphorus homeostasis. However, as kidney function declines, the ability of the kidneys to adequately excrete phosphorus is reduced. The hormonal changes that occur with CKD would suggest that the intestine should compensate for impaired renal phosphorus excretion by reducing fractional intestinal phosphorus absorption. However, limited studies in CKD animal models and patients with CKD suggest that there may be a break in this homeostatic response where the intestine fails to compensate. As many existing therapies for phosphate management in CKD are aimed at reducing absolute intestinal phosphorus absorption, better understanding of the factors that influence fractional and absolute absorption, the mechanism by which intestinal phosphate absorption occurs, and how CKD modifies these is a much-needed area of study.

scholarly journals R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)

2009 ◽  
Vol 24 (8) ◽  
pp. 2371-2377 ◽  
Author(s):  
S. M. Moe ◽  
M. F. Seifert ◽  
N. X. Chen ◽  
R. M. Sinders ◽  
X. Chen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Rat Model ◽  
Ectopic Calcification ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

scholarly journals Effectiveness of integrated care on delaying chronic kidney disease progression in rural communities of Thailand ( ESCORT ‐2) trials

Nephrology ◽  
2021 ◽  
Author(s):  
Teerawat Thanachayanont ◽  
Methee Chanpitakkul ◽  
Jukkapong Hengtrakulvenit ◽  
Podjanee Watcharakanon ◽  
Watcharapong Wisansak ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Rural Communities ◽  
Kidney Disease ◽  
Disease Progression ◽  
Integrated Care ◽  
Chronic Kidney Disease Progression ◽  
Kidney Disease Progression
Sign in / Sign up

Export Citation Format

Share Document